Sanofi reported EUR2.68B in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.

Selling And Administration Expenses Change Date
AbbVie USD 3.86B 350M Dec/2024
Amgen USD 1.62B 61M Sep/2024
AstraZeneca USD 5.25B 226M Sep/2024
Bristol-Myers Squibb USD 1.98B 55M Sep/2024
Canopy Growth CAD 40.93M 3.41M Sep/2024
Corcept Therapeutics USD 73.74M 6.81M Sep/2024
Drreddys Laboratories INR 21.15B 267M Sep/2024
Eli Lilly USD 2.1B 17.5M Sep/2024
Galapagos EUR 29.26M 3.88M Sep/2024
Genmab DKK 865M 29M Sep/2024
GlaxoSmithKline GBP 3.8B 1.41B Sep/2024
Glaxosmithkline GBP 3.77B 1.54B Sep/2024
Indivior 144M 1000K Jun/2024
J&J USD 6.45B 971M Dec/2024
Merck USD 2.66B 51M Sep/2024
Novartis USD 3.5B 368M Dec/2024
Novartis USD 3.13B 43M Sep/2024
Pacira USD 74.33M 6.2M Sep/2024
Perrigo USD 271.5M 29.3M Sep/2024
Pfizer USD 3.22B 341M Sep/2024
Prestige Brands USD 1.06B 991.72M Sep/2024
Roche Holding CHF 3.23B 3.29B Jun/2024
Sanofi EUR 2.68B 26M Sep/2024
Sanofi EUR 2.68B 26M Sep/2024
Supernus Pharmaceuticals USD 69.75M 16.15M Sep/2024
UCB EUR 533M 434M Jun/2024
Zoetis USD 565M 16M Sep/2024